United Therapeutics officer plans 8,300-share sale

UNITED THERAPEUTICS CORPORATION (UTHR) has a notice under Rule 144 indicating that officer Paul Mahon may sell 8,300 shares of common stock, expected to be issued from a stock option exercise on 08/20/2026, through Morgan Stanley Smith Barney LLC.

Rhea-AI Filing Summary

UNITED THERAPEUTICS CORPORATION (UTHR) has a notice under Rule 144 indicating that officer Paul Mahon may sell 8,300 shares of common stock, expected to be issued from a stock option exercise on 08/20/2026, through Morgan Stanley Smith Barney LLC. The notice also lists a series of sales by Mahon over the prior three months, each for 8,300 shares of common stock at various total sale values.

Key Figures

Shares to be sold: 8,300 shares Anticipated sale date: 08/20/2026 Recent sale 08/06/2026: 8,300 shares; 4291512.51 +2 more

5 metrics

Shares to be sold 8,300 shares Common stock to be sold for Paul Mahon’s account under Rule 144

Anticipated sale date 08/20/2026 Date associated with the planned sale of 8,300 shares

Recent sale 08/06/2026 8,300 shares; 4291512.51 Common stock sold by Paul Mahon on 08/06/2026

Recent sale 05/21/2026 8,300 shares; 4671398.80 Common stock sold by Paul Mahon on 05/21/2026

Broker Morgan Stanley Smith Barney LLC Listed as broker for the 8,300-share planned sale

Key Terms

Rule 144, Stock Option Exercise, Securities To Be Sold, Securities Sold During The Past 3 Months

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 08/20/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Securities To Be Sold financial

"144: Securities To Be Sold Common | 08/20/2026"

Securities Sold During The Past 3 Months financial

"144: Securities Sold During The Past 3 Months PAUL MAHON"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for UNITED THERAPEUTICS (UTHR)?

It discloses that officer Paul Mahon intends, under Rule 144, to sell 8,300 shares of UNITED THERAPEUTICS common stock, expected to be issued from a stock option exercise on 08/20/2026, using broker Morgan Stanley Smith Barney LLC.

How many UNITED THERAPEUTICS (UTHR) shares are covered by this Form 144?

The notice covers the potential sale of 8,300 shares of UNITED THERAPEUTICS common stock, expected to result from a stock option exercise dated 08/20/2023, with an anticipated sale date of 08/20/2026.

Who is selling UNITED THERAPEUTICS (UTHR) shares under this Form 144?

The planned sale is for the account of Paul Mahon, identified as an officer of UNITED THERAPEUTICS CORPORATION. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.

What recent UNITED THERAPEUTICS (UTHR) share sales by Paul Mahon are disclosed?

Over the past three months, the filing lists six sales by Paul Mahon, each for 8,300 shares of UNITED THERAPEUTICS common stock, with sale dates from 05/21/2026 through 08/06/2026 and total sale values between approximately 4,291,512.51 and 4,671,398.80.

What is the role of the broker in this UNITED THERAPEUTICS (UTHR) Form 144?

The notice lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the planned sale of 8,300 shares of UNITED THERAPEUTICS common stock, with the broker’s New York address provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2026 - 06:45 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001231589
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	UNITED THERAPEUTICS CORPORATION
SEC File Number	000-26301
Address of Issuer	1000 SPRING STREET SILVER SPRING MARYLAND 20910
Phone	(301) 608-9292
Name of Person for Whose Account the Securities are To Be Sold	PAUL MAHON
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8300	4342078.81	42890692	08/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2026	Stock Option Exercise	Issuer			8300	08/20/2023	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	08/06/2026	8300	4291512.51
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	07/16/2026	8300	4429637.79
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	07/02/2026	8300	4586274.56
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/18/2026	8300	4494840.93
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/04/2026	8300	4540642.45
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/21/2026	8300	4671398.80

144: Remarks and Signature

Remarks
Date of Notice	08/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Paul A. Mahon
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)